NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03040999,Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),https://clinicaltrials.gov/study/NCT03040999,,COMPLETED,The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).,YES,Head and Neck Neoplasms,BIOLOGICAL: Pembrolizumab|DRUG: Placebo|DRUG: Cisplatin|RADIATION: Accelerated Fractionation (AFX) Radiotherapy|RADIATION: Standard Fractionation (SFX) Radiotherapy,"Event-free Survival (EFS), EFS is the time from date of randomization to the date of first record of any of the following events: death due to any cause; progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR) or biopsy as indicated for locoregional progression or recurrence or distant metastasis. As well as the first record of the following types of surgery: salvage surgery for persistent or residual disease at the primary tumor site requiring surgical removal when invasive cancer is present on final pathology; neck dissection or surgery (performed for clinical or radiological disease progression per RECIST 1.1) ≤ 20 weeks from end of CRT when invasive cancer is present; or neck dissection or surgery \>20 weeks from end of CRT when invasive cancer is present. From product-limit (Kaplan-Meier) method for censored data., Up to approximately 62 months","Overall Survival (OS), OS is the time from randomization to death due to any cause, from product-limit (Kaplan-Meier) method for censored data. The hypothesis was that pembrolizumab in combination with CRT is superior to placebo in combination with CRT; but based on the protocol, because the statistical criterion for success in the primary EFS hypothesis was not met, the OS hypothesis was not tested, Up to approximately 62 months|Number of Participants With Adverse Events (AEs), An AE is any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE is any sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy., From time of first dose of study treatment until 90 days after last dose (up to approximately 19 months)|Number of Participants Discontinuing Study Drug Due to an AE, An AE is any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with the study drug. An AE is any sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy., From time of first dose of study treatment until the end of treatment (up to approximately 16 months)|Change From Baseline in Global Health Status/Quality of Life (GHS/QoL), The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) contains 30 items and measures five functional dimensions (physical, role, emotional, cognitive and social), three symptom items (fatigue, nausea/vomiting, and pain), six single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and QoL scale. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, so that a higher score indicates a better overall GHS. A change from baseline of 10 points on the 100-point EORTC QLQ-C30 scale is considered as clinically relevant. Based on a constrained longitudinal data analysis (cLDA) model with the patient reported outcomes (PRO) scores as the response variable with covariates for treatment, time, treatment by time interaction, and stratification factors of human papilloma virus (HPV) status and overall cancer stage., Prior to the first dose of study treatment (Baseline) and up to Week 45|Change From Baseline in Swallowing, Speech, and Pain Symptoms, EORTC QLQ Head and Neck Questionnaire (H\&N35) consists of 7 multi-item scales (pain in the mouth, problems with swallowing, senses, speech, social eating, social contact, and sexuality), Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Change from baseline in swallowing, speech, and pain symptoms was measured. A change from baseline of 10 points on the 100-point EORTC QLQ-H\&N35 is considered as clinically relevant. Based on a cLDA model with the PRO scores as the response variable with covariates for treatment, time, treatment by time interaction, and stratification factors of HPV status and overall cancer stage., Prior to the first dose of study treatment (Baseline) and up to Week 45|Change From Baseline in Physical Functioning, Participant responded to 5 questions from the EORTC QLQ-C30 about their physical functioning scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores were standardized, so that scores range from 0 to 100, where a higher score indicates a better quality of life. A change from baseline of 10 points on the 100-point scale is considered as clinically relevant. Based on a cLDA model with the PRO scores as the response variable with covariates for treatment, time, treatment by time interaction, and stratification factors of HPV status and overall cancer stage., Prior to the first dose of study treatment (Baseline) and up to Week 45",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,804,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",3475-412|MK-3475-412|173640|KEYNOTE-412|2016-003934-25,2017-04-05,2022-05-31,2024-08-21,2017-02-02,2023-06-08,2024-09-19,"UCLA Medical Center ( Site 0273), Los Angeles, California, 90095, United States|University of California San Francisco ( Site 0274), San Francisco, California, 94115, United States|St. Joseph Heritage Healthcare ( Site 0254), Santa Rosa, California, 95403, United States|Smilow Cancer Hospital at Yale New Haven ( Site 0256), New Haven, Connecticut, 06510, United States|Rush University Medical Center ( Site 0260), Chicago, Illinois, 60612, United States|Indiana University ( Site 0264), Indianapolis, Indiana, 46202, United States|Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital ( Site 0281), Baton Rouge, Louisiana, 70809, United States|University of Massachusetts Memorial Medical Center ( Site 0285), Worcester, Massachusetts, 01655, United States|University of Michigan Hospital and Health Systems ( Site 0267), Ann Arbor, Michigan, 48109, United States|Barbara Ann Karmanos Cancer Institute ( Site 0272), Detroit, Michigan, 48201, United States|Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center ( Site 0290), Springfield, Missouri, 65804, United States|St. Vincent Healthcare Frontier Cancer Center ( Site 0286), Billings, Montana, 59102, United States|Comprehensive Cancer Centers of Nevada ( Site 8004), Las Vegas, Nevada, 89169, United States|University of Rochester - James P. Wilmot Cancer Center ( Site 0255), Rochester, New York, 14642, United States|Oncology Hematology Care, Inc. ( Site 8003), Cincinnati, Ohio, 45242, United States|Willamette Valley Cancer Institute and Research Center ( Site 8000), Eugene, Oregon, 97401, United States|St. Luke's Cancer Center - Anderson ( Site 0251), Easton, Pennsylvania, 18045, United States|St. Francis Hospital Cancer Center ( Site 1461), Greenville, South Carolina, 29607, United States|Texas Oncology-Arlington North ( Site 8005), Arlington, Texas, 76014, United States|Texas Oncology-Austin Central ( Site 8002), Austin, Texas, 78731, United States|Texas Oncology PA ( Site 8001), Longview, Texas, 75601, United States|University of Virginia Health System ( Site 0261), Charlottesville, Virginia, 22908, United States|Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0269), Seattle, Washington, 98109, United States|Medical Oncology Associates (Summit Cancer Centers) ( Site 0257), Spokane, Washington, 99208, United States|Liverpool Hospital ( Site 0301), Liverpool, New South Wales (Australia), 2170, Australia|Blacktown Hospital Western Sydney Local Health District ( Site 0304), Blacktown, New South Wales, 2148, Australia|Princess Alexandra Hospital ( Site 0305), Brisbane, Queensland, 4102, Australia|Royal Brisbane and Women s Hospital ( Site 0302), Herston, Queensland, 4029, Australia|Royal Adelaide Hospital ( Site 0303), Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Centre ( Site 0300), Melbourne, Victoria, 3000, Australia|Landeskrankenhaus - Universitatsklinikum Graz ( Site 0601), Graz, 8036, Austria|Krankenhaus der Barmherzigen Schwestern Linz ( Site 0603), Linz, 4010, Austria|Landeskrankenhaus Salzburg ( Site 0600), Salzburg, 5020, Austria|Allgemeines Krankenhaus der Stadt Wien ( Site 0602), Vienna/Wien, 1090, Austria|Cliniques Universitaires Saint Luc - Bruxelles ( Site 0651), Brussels, 1200, Belgium|UZ Gent ( Site 0650), Gent, 9000, Belgium|UZ Leuven Campus Gasthuisberg ( Site 0652), Leuven, 3000, Belgium|C.H.U. Sart Tilman-Service d'Oncologie Medicale ( Site 0654), Liege, 4000, Belgium|Clinique et Maternite Sainte-Elisabeth ( Site 0653), Namur, 5000, Belgium|Hospital Santa Izabel - Santa Casa de Misericordia da Bahia ( Site 0006), Salvador, Bahia, 40050-410, Brazil|Centro Regional Integrado de Oncologia ( Site 0002), Fortaleza, Ceara, 60336-045, Brazil|Liga Norte Riograndense Contra o Cancer ( Site 0005), Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0001), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de Clinicas de Porto Alegre ( Site 0011), Porto Alegre, RS, 90035-903, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0003), Barretos, Sao Paulo, 14784-400, Brazil|Instituto do Cancer de Sao Paulo - ICESP ( Site 0004), Sao Paulo, SP, 01246-000, Brazil|Hospital das Clinicas da FMUSP de Ribeirao Preto ( Site 0008), Ribeirao Preto, 14048-900, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0010), Rio de Janeiro, 20230-130, Brazil|Tom Baker Cancer Centre ( Site 0063), Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute ( Site 0064), Edmonton, Alberta, T6G 1Z2, Canada|Juravinski Cancer Centre ( Site 0062), Hamilton, Ontario, L8V 5C2, Canada|London Health Sciences Centre ( Site 0055), London, Ontario, N6A 4L6, Canada|The Ottawa Hospital - Cancer Care ( Site 0052), Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Centre ( Site 0051), Toronto, Ontario, M5G 1X5, Canada|McGill University Health Centre ( Site 0061), Montreal, Quebec, H4A 3J1, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0057), Sherbrooke, Quebec, J1H 5N4, Canada|Hospital Pablo Tobon Uribe ( Site 0151), Medellin, Antioquia, 050034, Colombia|Fundacion Valle del Lili ( Site 0150), Cali, Valle Del Cauca, 760032, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0156), Cali, Valle Del Cauca, 760042, Colombia|Centro de Investigacion Clinica del Country ( Site 0155), Bogota, 110221, Colombia|FN Brno. ( Site 0703), Brno, 625 00, Czechia|Fakultni Nemocnice Hradec Kralove ( Site 0705), Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc ( Site 0701), Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava ( Site 0702), Ostrava, 708 52, Czechia|Nemocnice Na Bulovce ( Site 0700), Praha 8, 180 81, Czechia|2. LF UK a FN Motol ( Site 0704), Praha, 150 06, Czechia|Centre Jean Bernard Laboratoire Mahe Meziani ( Site 0760), Le Mans, 72000, France|Clinique Francois Chenieux ( Site 0757), Limoges, 87039, France|Institut Claudius Regaud ( Site 0754), Toulouse Cedex 09, 31059, France|Institut De Cancerologie De Lorraine ( Site 0758), Vandoeuvre les Nancy, 54500, France|Institut Gustave Roussy ( Site 0759), Villejuif, 94805, France|Universitätsklinikum Erlangen ( Site 0801), Erlangen, 91054, Germany|SRH Waldklinikum Gera GmbH ( Site 0802), Gera, 07548, Germany|Universitares Cancer Center Hamburg - UCCH ( Site 0811), Hamburg, 20246, Germany|Medizinische Hochschule Hannover ( Site 0807), Hannover, 30325, Germany|Universitaetsklinikum Schleswig-Holstein-Campus Luebeck ( Site 0803), Luebeck, 23538, Germany|Klinikum der Universitaet Munchen ( Site 0810), Munchen, 81377, Germany|Universitaetsklinik Ulm ( Site 0804), Ulm, 89075, Germany|Rambam MC ( Site 0903), Haifa, 3109601, Israel|Hadassah Ein Karem Jerusalem ( Site 0902), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 0904), Petah Tikva, 4941492, Israel|Sheba MC ( Site 0901), Ramat Gan, 5265601, Israel|Tel Aviv Sourasky Medical Center ( Site 0900), Tel Aviv, 6423906, Israel|Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0954), Modena, MO, 41124, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 0955), Firenze, 50134, Italy|Istituto Nazionale Tumori ( Site 0950), Milano, 20133, Italy|Istituto Europeo di Oncologia ( Site 0953), Milano, 20141, Italy|Azienda Ospedaliera San Paolo ( Site 0952), Milano, 20142, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0951), Napoli, 80121, Italy|Istituto Oncologico Veneto ( Site 0957), Padova, 35128, Italy|Fondazione IRCCS - Policlinico San Matteo ( Site 0960), Pavia, 27100, Italy|National Cancer Center Hospital East ( Site 0350), Kashiwa, Chiba, 277-8577, Japan|Hokkaido University Hospital ( Site 0351), Sapporo, Hokkaido, 060-8648, Japan|Hyogo Cancer Center ( Site 0354), Akashi, Hyogo, 673-8558, Japan|Kagawa University Hospital ( Site 0359), Kita-gun, Kagawa, 761-0793, Japan|Miyagi Cancer Center ( Site 0353), Natori, Miyagi, 981-1293, Japan|Chiba Cancer Center ( Site 0358), Chiba, 260-8717, Japan|Hiroshima University Hospital ( Site 0352), Hiroshima, 734-8551, Japan|Osaka International Cancer Institute ( Site 0355), Osaka, 541-8567, Japan|Medical Hospital, Tokyo Medical And Dental University ( Site 0356), Tokyo, 113-8519, Japan|The Cancer Institute Hospital of JFCR ( Site 0357), Tokyo, 135-8550, Japan|Chungbuk National University Hospital ( Site 0454), Cheongju si, Chungcheongbuk Do, 28644, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0453), Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Chungnam National University Hospital ( Site 0455), Daejeon, 35015, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0452), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 0450), Seoul, 06351, Korea, Republic of|Noordwest Ziekenhuisgroep NWZ ( Site 1350), Alkmaar, 1815 JD, Netherlands|VU Medisch Centrum ( Site 1352), Amsterdam, 1081 HV, Netherlands|UMCG ( Site 1351), Groningen, 9713 GZ, Netherlands|UMC St. Radboud ( Site 1356), Nijmegen, 6525 GA, Netherlands|Erasmus University Medical Center ( Site 1354), Rotterdam, 3015 GD, Netherlands|Capital & Coast District Health Board - Wellington Hospital ( Site 0400), Wellington, Newtown, 6021, New Zealand|Dolnoslaskie Centrum Onkologii. ( Site 1001), Wroclaw, Dolnoslaskie, 53-413, Poland|Mazowiecki Szpital Onkologiczny ( Site 1015), Wieliszew, Mazowieckie, 05-135, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1005), Bielsko-Biala, 43-300, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1007), Gdynia, 81-519, Poland|Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie ( Site 1010), Gliwice, 44-101, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1008), Krakow, 31-826, Poland|Zachodniopomorskie Centrum Onkologii ( Site 1013), Szczecin, 71-730, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie ( Site 1000), Warszawa, 02-781, Poland|H.U. Vall de Hebron ( Site 1052), Barcelona, 08035, Spain|Hospital Duran i Reynals ( Site 1053), Hospitalet de Llobregat, 08907, Spain|Hospital Doce de Octubre ( Site 1054), Madrid, 28024, Spain|Hospital Universitario Ramon y Cajal ( Site 1055), Madrid, 28034, Spain|Hospital Clinico San Carlos ( Site 1051), Madrid, 28040, Spain|Hospital Universitario Virgen de la Victoria ( Site 1056), Malaga, 29010, Spain|Hospital Gral Universitario de Valencia ( Site 1050), Valencia, 46014, Spain|Chang Gung Medical Foundation - Kaohsiung ( Site 0501), Kaohsiung, 83301, Taiwan|Taichung Veterans General Hospital ( Site 0506), Taichung, 407, Taiwan|National Cheng Kung University Hospital ( Site 0503), Tainan, 70403, Taiwan|National Taiwan University Hospital ( Site 0500), Taipei, 10048, Taiwan|MacKay Memorial Hospital ( Site 0505), Taipei, 105, Taiwan|Taipei Veterans General Hospital ( Site 0504), Taipei, 112, Taiwan|Linkou Chang Gung Memorial Hospital ( Site 0502), Taoyuan, 333, Taiwan|Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1103), Adana, 01250, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1102), Ankara, 06100, Turkey|Ankara Sehir Hastanesi ( Site 1108), Ankara, 06800, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1100), Istanbul, 34093, Turkey|Medipol Universite Hastanesi ( Site 1104), Istanbul, 34214, Turkey|Medical Park Izmir Hastanesi ( Site 1109), Izmir, 35520, Turkey|Kocaeli Universitesi Tip Fakultesi ( Site 1106), Kocaeli, 41380, Turkey|Inonu Universitesi Tip Fakultesi ( Site 1101), Malatya, 44280, Turkey|Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 1206), Norwich, Norfolk, NR4 7UY, United Kingdom|University Hospital of North Staffordshire ( Site 1202), Stoke-On-Trent, Staffordshire, ST4 6QG, United Kingdom|Ipswich Hospital ( Site 1207), Ipswich, Suffolk, IP4 5PD, United Kingdom|St Bartholomew s Hospital ( Site 1205), London, EC1A 7BE, United Kingdom|The Royal Marsden Foundation Trust ( Site 1200), London, SW3 6JJ, United Kingdom|Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 1204), London, W6 8RF, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1208), Preston, PR2 9HT, United Kingdom|University Hospital Southampton NHS Foundation Trust ( Site 1203), Southampton, SO16 6YD, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 1201), Sutton, SM2 5PT, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/99/NCT03040999/Prot_SAP_000.pdf"
